Motti Farbstein

492 total citations
7 papers, 193 citations indexed

About

Motti Farbstein is a scholar working on Oncology, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Motti Farbstein has authored 7 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Physiology and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Motti Farbstein's work include Adenosine and Purinergic Signaling (4 papers), Peptidase Inhibition and Analysis (2 papers) and Click Chemistry and Applications (1 paper). Motti Farbstein is often cited by papers focused on Adenosine and Purinergic Signaling (4 papers), Peptidase Inhibition and Analysis (2 papers) and Click Chemistry and Applications (1 paper). Motti Farbstein collaborates with scholars based in Israel, United States and Serbia. Motti Farbstein's co-authors include Pnina Fishman, Michael H. Silverman, Sara Bar‐Yehuda, William Kerns, Shira Cohen, R. Patoka, Salomon M. Stemmer, Ofer Benjaminov, G. Zajicek and Hanan Farbstein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Motti Farbstein

7 papers receiving 182 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Motti Farbstein Israel 5 109 71 43 36 25 7 193
Jonathan Matalonga Spain 6 20 0.2× 76 1.1× 39 0.9× 48 1.3× 61 2.4× 7 220
Kevin Muñoz Forti United States 10 66 0.6× 104 1.5× 38 0.9× 18 0.5× 19 0.8× 16 293
Cibele S. Pinto United States 10 38 0.3× 273 3.8× 17 0.4× 21 0.6× 16 0.6× 16 404
Adam M. Lopez United States 11 32 0.3× 171 2.4× 37 0.9× 33 0.9× 30 1.2× 24 339
Francesca Pierella Italy 6 91 0.8× 211 3.0× 141 3.3× 70 1.9× 21 0.8× 7 382
Hanna Artsi Israel 6 21 0.2× 167 2.4× 48 1.1× 47 1.3× 9 0.4× 7 301
Annette E. Patterson Canada 3 30 0.3× 110 1.5× 81 1.9× 39 1.1× 147 5.9× 5 302
Rachel S. Fletcher United Kingdom 7 62 0.6× 48 0.7× 60 1.4× 31 0.9× 4 0.2× 7 182
Adeleye Opejin United States 8 25 0.2× 79 1.1× 62 1.4× 13 0.4× 251 10.0× 9 372
Ilan Cohn United Kingdom 3 129 1.2× 72 1.0× 20 0.5× 4 0.1× 17 0.7× 4 166

Countries citing papers authored by Motti Farbstein

Since Specialization
Citations

This map shows the geographic impact of Motti Farbstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motti Farbstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motti Farbstein more than expected).

Fields of papers citing papers by Motti Farbstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motti Farbstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motti Farbstein. The network helps show where Motti Farbstein may publish in the future.

Co-authorship network of co-authors of Motti Farbstein

This figure shows the co-authorship network connecting the top 25 collaborators of Motti Farbstein. A scholar is included among the top collaborators of Motti Farbstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motti Farbstein. Motti Farbstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Lencioni, Riccardo, Salomon M. Stemmer, Motti Farbstein, et al.. (2024). A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report. Experimental and Therapeutic Medicine. 27(6). 263–263. 2 indexed citations
2.
Safadi, Rifaat, Marius Braun, Yael Milgrom, et al.. (2021). Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis. Alimentary Pharmacology & Therapeutics. 54(11-12). 1405–1415. 28 indexed citations
4.
Stemmer, Salomon M., Ofer Benjaminov, Michael H. Silverman, et al.. (2012). CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study.. Journal of Clinical Oncology. 30(15_suppl). e14731–e14731. 2 indexed citations
5.
Stemmer, Salomon M., Ofer Benjaminov, Michael H. Silverman, et al.. (2012). CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. The Oncologist. 18(1). 25–26. 77 indexed citations
6.
Ochaion, Avivit, Sara Bar‐Yehuda, Luis Del Valle, et al.. (2006). Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3adenosine receptor expression. Arthritis Research & Therapy. 8(6). R169–R169. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026